Featured Study Opportunities
The Crohn's & Colitis Foundation utilizes Featured Study Opportunities to collaborate with academic and industry researchers to help enroll patients with Crohn’s disease and ulcerative colitis into clinical studies. The list below highlights our partners' current research studies. Please note that these partners have paid to have their trials posted below. Some partners' studies listed may be recipients of partial or full funding from the Crohn's & Colitis Foundation. This support does not imply recommendation or favor of the Foundation, as the Crohn's & Colitis Foundation does not endorse any particular study.
For a comprehensive listing of all research studies currently recruiting, please click here.
(For e.g NY instead of New York)
Current Results: 27 entries
To evaluate the efficacy and safety of ozanimod in pediatric participants with moderately to severely active UC.
To evaluate the efficacy of ozanimod in pediatric participants with moderately to severely active Crohn's disease.
To evaluate the effect of efavaleukin alfa on induction of clinical remission.
Primary: To determine whether AVB-114 compared to standard of care treatment is effective in inducing remission of the treated complex perianal fistula in patients with Crohn’s Disease.
Secondary: To assess clinical and radiologic components of fistula remission, safety of treatment, disease activity, patient Quality of Life, and patient care journey, between AVB-114 and standard of care treatment.
- To prevent relapse in patients with Ulcerative Colitis (UC) in remission after administering fecal microbiota transplant (FMT) capsules plus Standard-Of-Care (SOC) treatment compared to placebo plus SOC treatment for 12 weeks.
- To evaluate the safety of FMT capsules given orally for 12 weeks in patients with UC in remission.
To assess the safety of, as well as how a natural product derived from the Hops plant is broken down by the bacteria in the intestines of adults with Crohn’s disease.
To Evaluate the Safety and Efficacy of PN-943 Treatment in Patients with Moderate to Severe Active Ulcerative Colitis.
To assess the safety and tolerability and early proof of efficacy of TAK-018 in patients with Crohn’s Disease who are planning to undergo surgery to remove the diseased ileo-cecal region of the bowel.
To evaluate the dose-response relationship of two doses of etrasimod versus placebo as induction therapy in participants with moderately to severely active Crohn’s disease.
The purpose of the study is to evaluate the safety and effectiveness of the study medicine in adults with ulcerative colitis.
The Featured Study Opportunities page is made possible in part by: